| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
BLA Filing example | BLA | — | Subscribe to access the data. | Gene Therapies | Rare Diseases | ||
BLA Filing example | BLA | — | Subscribe to access the data. | Gene Therapies | Rare Diseases | ||
BLA Filing example | BLA | — | Subscribe to access the data. | Gene Therapies | Rare Diseases |
Recent Updates
Recently added Catalysts
Intellia Therapeutics, Inc.$14.22
-1.22 (-7.93%)
C 51Pipeline Score Overvalued Biotech · Clinical
Market Cap
1.76 B
EPS
-3.53
P/E Ratio
-
Value Trade
39.73 M
SEC Financials
Q1 2026Dilution Risk
Revenue
15.05 M
R&D Expenses
80.74 M
Operating CF
-117.35 M
Total Assets
758.78 M
Total Liabilities
137.84 M
Equity
620.94 M
D/E Ratio
12,345
-5.62 %
Week
-19.8 %
1 Month
-1.49 %
3 Month
54.6 %
6 Month
-80.44 %
5 Year
-42.73 %
All Time
Cash Data
Cash Position
375.99 M
Monthly Burn
39.12 M
Runway
7.6 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
6.18 M
52 Week Range
6.83 - 28.25
% held by Insiders
4.44 %
% held by Institutions
76.46 %
Enterprise Value
1.47 B
Total Shares
115.89 M
Short %
51.23 %
Float Shares
96.07 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Intellia Therapeutics, Inc.
682Total events
15Upcoming
123Tier-1 (high impact)
2016 – 2028Coverage
Upcoming catalysts 15
Event history 667
Q3 2026
●NDA Submissionlonvoguran ziclumeranRegulatory Filing
Anticipates completing BLA submission in 2H 2026
hereditary angioedemasource ↗
Q3 2026
▲Enrollment Completenexiguran ziclumeranTrial
Plan to complete patient enrollment in MAGNITUDE-2 in second half of 2026
Hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)source ↗
Q3 2026
●BLA Submissionlonvo-zRegulatory Filing
Plan to complete BLA submission in second half of 2026
Hereditary Angioedema (HAE)source ↗
Q3 2026
◆BLA Submissionlonvoguran ziclumeranRegulatory Filing
BLA submission planned
hereditary angioedemasource ↗
Jun 13, 2026
▲Oral Presentationlonvo-zPresentation
Late-breaking oral presentation of additional positive Phase 3 results for lonvo-z at EAACI 2026
hereditary angioedemasource ↗
Jun 13, 2026
▲Publicationlonvo-zPresentation
HAELO manuscript simultaneously published in the New England Journal of Medicine
hereditary angioedemasource ↗
Jun 13, 2026
▲Primary Endpoint Metlonvo-zClinical Data
HAELO met primary endpoint with 87% reduction in mean monthly attacks
hereditary angioedemasource ↗
Jun 13, 2026
▲Secondary Endpoint Datalonvo-zClinical Data
Key secondary endpoints met: 89% reduction in attacks requiring on-demand treatment, 91% reduction in moderate/severe attacks, and significant AE-QoL improvement
hereditary angioedemasource ↗
Jun 12, 2026
◆Poster PresentationPresentation
Poster presentation on barriers to normalization among HAE patients in Europe at EAACI 2026
hereditary angioedemasource ↗
Jun 12, 2026
◆Oral Presentationlonvo-zPresentation
Additional clinical data from HAELO to be presented at EAACI Congress
Hereditary Angioedema (HAE)source ↗
Jun 12, 2026
◆Oral Presentationlonvoguran ziclumeranPresentation
Additional HAELO data to be presented at EAACI Congress 2026
hereditary angioedemasource ↗
Jun 3, 2026
◆Oral PresentationPresentation
Intellia management to participate in fireside chat at Jefferies Global Healthcare Conference
Drug Pipeline Intelligence
C51
Pipeline Score $906M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.5x
rNPV / MCap Top 77%
Micro Cap (rank 211 of 912)
Percentile RankIntellia Therapeutics, Inc. carries a moderate pipeline score (51/100), with $3.0B risk-adjusted pipeline value, led by NTLA-2002 in Hereditary Angioedema (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NTLA-2002 Monoclonal antibody | Hereditary Angioedema | Phase 3 | NCT06634420 | 90% | $1.4B | ACTIVE NOT_RECRUITING | 80 | FAST | B (70) | Sep 1, 2027 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
lonvoguran ziclumeran RMATOrphan | hereditary angioedema | Phase 3 | 2026-06-13 | 87% reduction in mean monthly attacks; 62% of patients in the lonvo-z arm were entirely attack free; 11% of patients in the placebo arm were entirely attack free Read More | Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Read More | |
lonvoguran ziclumeran RMATOrphan | hereditary angioedema | Phase 3 | 2026-06-13 | 87% reduction in mean monthly attacks; 62% of patients in the lonvo-z arm were entirely attack free; 11% of patients in the placebo arm were entirely attack free Read More | Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Read More | |
lonvoguran ziclumeran RMATOrphan | hereditary angioedema | Phase 3 | 2026-06-13 | 87% reduction in mean monthly attacks; 62% of patients in the lonvo-z arm were entirely attack free; 11% of patients in the placebo arm were entirely attack free Read More | Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NTLA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NTLA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NTLA▲ +23.2%on this news
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Intellia Therapeutics presented promising Phase 3 results for lonvo-z in treating hereditary angioedema at the EAACI Annual Congress 2026. The trial demonstrated an 87% reduction in monthly attacks and a significant portion of patients remained attack-free. The findings were published in the New England Journal of Medicine, supporting the drug's potential for regulatory approval in 2027.
Read more →NTLA▼ -8.2%on this news
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. has announced inducement grants to six new employees, comprising 47,150 restricted stock units (RSUs) as part of its 2024 Inducement Plan. The RSUs will vest over three years, contingent on the employees' continued service. This initiative aims to attract talent while complying with Nasdaq Listing Rule 5635(c)(4). Intellia continues to prioritize advancements in CRISPR gene editing technologies.
Read more →NTLAIntellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
Intellia Therapeutics will present additional Phase 3 data for lonvo-z at the EAACI Annual Congress 2026. The study focuses on hereditary angioedema (HAE) and will include a late-breaking oral presentation and a poster on patient burdens. Lonvo-z aims to be a groundbreaking CRISPR-based treatment for HAE.
Read more →NTLAIntellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics reported positive Phase 3 results for lonvo-z, a CRISPR-based treatment for hereditary angioedema (HAE), showing an 87% reduction in attacks. The company initiated a rolling BLA submission to the FDA, aiming for a U.S. launch in early 2027. Additionally, patient screening for nex-z in ATTR amyloidosis trials has resumed, and Intellia's financial resources are projected to support operations through at least 2028.
Read more →NTLAIntellia Therapeutics to Participate in Upcoming Investor Conferences
Intellia Therapeutics, Inc. has announced its participation in several upcoming investor conferences, including the Bank of America Securities Health Care Conference, RBC Capital Markets Global Healthcare Conference, and Jefferies Global Healthcare Conference. The fireside chats will provide opportunities for management to discuss the company's advancements in CRISPR gene editing and other technologies. Webcasts of these presentations will be available live, with replays accessible for 90 days afterward. Intellia's focus remains on developing potentially curative treatments for severe diseases.
Read more →NTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Intellia Therapeutics announced the awarding of inducement grants to 43 new employees under its 2024 Inducement Plan. The grants, totaling 208,850 shares in restricted stock units (RSUs), will vest over three years, contingent on continued employment. This move is part of Intellia's strategy to attract talent and is compliant with Nasdaq regulations.
Read more →NTLA▼ -5.7%on this newsshared move
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
Intellia Therapeutics has announced the pricing of a public offering of 16,744,187 shares at $10.75 each, aiming to raise around $180 million. The offering is underwritten by Jefferies, Goldman Sachs, and Citigroup, with a 30-day option for underwriters to purchase additional shares. The completion of the offering is subject to market conditions.
Read more →NTLAIntellia Announces Proposed Public Offering of Common Stock
Intellia Therapeutics has announced a proposed public offering of $150 million in common stock. The offering includes a 30-day option for underwriters to purchase an additional 15% of the shares. The offering is subject to market conditions, and the company aims to leverage its CRISPR gene editing technology to advance its clinical programs.
Read more →NTLAIntellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Intellia Therapeutics announced positive results from the Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema. The trial met its primary and all key secondary endpoints, demonstrating a significant reduction in HAE attacks. A rolling biologics license application has been initiated with the FDA, aiming for a potential U.S. launch in early 2027.
Read more →NTLAIntellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
Intellia Therapeutics has initiated a rolling submission of a biologics license application (BLA) to the FDA for its CRISPR-based treatment, lonvo-z, for hereditary angioedema (HAE). The Phase 3 HAELO trial showed promising results, meeting all primary and secondary endpoints. If approved, lonvo-z could be the first in vivo CRISPR therapy, potentially transforming HAE treatment.
Read more →NTLACONFIDENTIAL *** Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all
Intellia Therapeutics announced positive results from its Phase 3 HAELO trial of lonvo-z, a CRISPR gene editing therapy for hereditary angioedema. This trial marks the first Phase 3 data reported for in vivo gene editing, potentially changing the treatment landscape for patients suffering from this rare genetic condition. The novel therapy aims to provide a one-time solution to reduce the genetic causes of angioedema, with a proposed U.S. launch planned for 2027. Regulatory submissions have begun to seek approval from the FDA.
Read more →NTLA▼ -14.1%on this newsshared move
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
Intellia Therapeutics announced it will report topline data from its Phase 3 HAELO clinical trial for lonvoguran ziclumeran in hereditary angioedema on April 27, 2026. This marks the world's first Phase 3 readout for an in vivo CRISPR gene editing candidate. The company will host a webcast to discuss the findings, showcasing its commitment to transparency.
Read more →NTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6, 2026
Intellia Therapeutics announced the awarding of inducement grants to six new employees under its 2024 Inducement Plan. These grants, consisting of 16,500 restricted stock units, are designed to incentivize new hires as part of the company's strategy to enhance its workforce. The awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Read more →NTLA▼ -11.9%on this newsshared move
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
Intellia Therapeutics presented promising long-term data on Lonvoguran Ziclumeran (Lonvo-z) at the AAAAI 2026 meeting. The Phase 1/2 study showed a significant reduction in HAE attack rates, with most patients remaining attack-free for extended periods. The investigational therapy aims to provide a one-time treatment solution for hereditary angioedema, leveraging CRISPR technology.
Read more →NTLA▲ +12%on this newsshared move
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
Intellia Therapeutics announced that the FDA has lifted the clinical hold on its MAGNITUDE Phase 3 trial for nexiguran ziclumeran (nex-z) in patients with ATTR-CM. The company has aligned with the FDA on enhanced safety measures to resume enrollment in both MAGNITUDE and MAGNITUDE-2 trials. Nex-z aims to be a one-time treatment for transthyretin amyloidosis.
Read more →NTLA▲ +12%on this newsshared move
AMENDMENT NO. 2
Intellia Therapeutics, Inc. has made an amendment to its Open Market Sale Agreement with Jefferies LLC, increasing the financial cap to approximately $1.04 billion. The agreement has been adjusted to include new details such as an updated issuance notice and changes to the contact person. Additionally, the company plans to file a Prospectus Supplement in compliance with regulatory standards. This amendment reflects ongoing financial strategies to enhance capital supply.
Read more →NTLA▲ +6.4%on this newsshared move
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Intellia Therapeutics reported its financial results for Q4 and full-year 2025, highlighting significant progress in its clinical trials. The company is preparing for a potential launch of lonvo-z for Hereditary Angioedema (HAE) and aims to resolve clinical holds on its nex-z trials. The upcoming year is expected to be pivotal with topline Phase 3 data and a planned BLA submission for lonvo-z.
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Intellia Therapeutics, a clinical-stage gene editing company, has announced it will hold a conference call on February 26, 2026, to review its fourth quarter and full-year 2025 financial results, alongside key business updates. This meeting aims to provide insights into the company's performance and strategic direction. The call can be joined via teleconference or webcast, with a replay available for a limited time thereafter. Intellia continues to emphasize its commitment to pioneering CRISPR-based therapies.
Read more →NTLA▼ -6.8%on this news
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
Intellia Therapeutics announced that the FDA has lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). The company plans to resume patient enrollment promptly. However, the FDA had previously imposed a hold due to safety concerns related to liver function tests.
Read more →NTLAIntellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities Litigation Reform Ac
Intellia Therapeutics has outlined its progress and future goals concerning its product candidates lonvoguran ziclumeran (lonvo-z) and nexiguran ziclumeran (nex-z). The company aims to present topline data from a Phase 3 trial for lonvo-z by mid-2026 and submit a biologics license application later that year. However, both programs face challenges, including clinical holds on the nex-z trials, which could impact timelines. Despite these challenges, the outcomes of these therapies could significantly affect treatment for hereditary angioedema and transthyretin amyloidosis.
Read more →NTLAIntellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Intellia Therapeutics, a clinical-stage gene editing company, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will showcase their advancements in CRISPR-based therapies. A live webcast will be accessible on their website, with a replay available for 30 days.
Read more →NTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 2, 2026
Intellia Therapeutics has announced the awarding of inducement grants to two new employees as part of its 2024 Inducement Plan. The grants, totaling 22,800 restricted stock units, will vest over three years, contingent on continued employment. This move is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to strengthen the company's talent pool.
Read more →NTLAIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 5, 2025
Intellia Therapeutics announced the awarding of inducement grants to three new employees under its 2024 Inducement Plan. The grants, consisting of 12,600 restricted stock units, will vest over three years, contingent on continued employment. This initiative aims to attract talent and support the company's innovative gene editing efforts.
Read more →NTLAIntellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
Intellia Therapeutics presented positive long-term Phase 1 data for its investigational product, nexiguran ziclumeran (nex-z), in patients with transthyretin amyloidosis with cardiomyopathy. The trial showed significant reductions in TTR levels and stabilization or improvement in various clinical markers over 24 months. However, the company is currently addressing a clinical hold imposed by the FDA on its Phase 3 trials.
Read more →NTLAIntellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Intellia Therapeutics has presented positive pooled data from its Phase 1/2 trial of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema, showing that 97% of patients were attack-free and LTP-free after treatment. The results were shared at the ACAAI 2025 Annual Scientific Meeting, highlighting the potential of lonvo-z to redefine HAE treatment. The ongoing Phase 3 HAELO trial is expected to provide topline results by mid-2026.
Read more →NTLA▼ -22.7%on this newsshared move
Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates
Intellia Therapeutics reported its third quarter 2025 financial results and updates on its clinical trials. The company announced a patient death related to liver complications in the MAGNITUDE Phase 3 trial of nexiguran ziclumeran (nex-z), leading to a clinical hold by the FDA. Despite this setback, Intellia remains optimistic about the potential of nex-z and has completed enrollment for the lonvoguran ziclumeran (lonvo-z) trial.
Read more →NTLA▼ -42.2%on this news
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
Intellia Therapeutics has paused patient dosing and screening in its MAGNITUDE and MAGNITUDE-2 Phase 3 trials for nex-z due to a serious adverse event in a patient. The company is consulting with experts and regulatory authorities to ensure patient safety and to strategize on resuming enrollment. Over 650 patients are currently enrolled in these trials.
Read more →NTLA▼ -6.5%on this news
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy One dose of nex-z led to rapid, deep and
Intellia Therapeutics announced positive longer-term data from its Phase 1 study of nexiguran ziclumeran (nex-z) for hereditary transthyretin amyloidosis with polyneuropathy. The data showed deep and durable reductions in serum TTR levels among patients after a single dose, with many experiencing stability or improvement in clinical measures. The Phase 3 MAGNITUDE-2 trial is progressing, with the expectation of completing enrollment by mid-2026 and a potential BLA submission by 2028. The results highlight the promise of nex-z as a transformative treatment for ATTR amyloidosis.
Read more →NTLA▲ +10.7%on this newsshared move
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Intellia Therapeutics will present longer-term data from its ongoing Phase 1 trial of nex-z for hereditary ATTR amyloidosis with polyneuropathy at the upcoming International ATTR Amyloidosis Meeting. The presentation will include up to three years of patient follow-up and aims to highlight the efficacy and safety of the investigational CRISPR-based treatment. This could mark a significant advancement in the treatment of this rare disease.
Read more →NTLA▲ +29.8%on this newsshared move
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema
Intellia Therapeutics has completed patient enrollment for the global Phase 3 HAELO study of lonvoguran ziclumeran (lonvo-z), aimed at treating hereditary angioedema (HAE). Nearly half of the participants were enrolled from the U.S., and topline data is expected in the first half of 2026. The company plans to submit a biologics license application in the second half of 2026, targeting a U.S. launch in the first half of 2027. Lonvo-z is a CRISPR-based therapy designed to significantly reduce HAE attacks and has received multiple regulatory designations.
Read more →NTLAIntellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress • Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomy
Intellia Therapeutics reported positive financial results for Q2 2025, with significant progress in their clinical trials, including the global Phase 3 MAGNITUDE trial for nexiguran ziclumeran in ATTR-CM. The trial is expected to exceed its enrollment targets, with plans to expand to approximately 1,200 patients. In addition, Intellia's financial position is strong, with enough funding to support operations into 2027. Upcoming data presentations and trial completions are anticipated in the second half of 2025, further promoting their innovative CRISPR-based therapies.
Read more →NTLAIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics (NASDAQ: NTLA) announced an inducement grant of 18,200 restricted stock units (RSUs) to five new employees on August 1, 2025. This grant is part of Intellia's 2024 Inducement Plan and serves as a material inducement to employment. The RSUs will vest over three years, contingent on the employees' continued service. This initiative highlights Intellia's efforts to enhance its workforce as it continues to develop CRISPR-based therapies.
Read more →NTLA▼ -5.6%on this newsshared move
INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Intellia Therapeutics, Inc. regarding potential breaches of fiduciary duties related to a class action complaint. The investigation is prompted by disclosures that the company would cease research on NTLA-3001, impacting its stockholders. Following the announcement of a reorganization and workforce reduction, Intellia's stock price experienced a significant decline. The law firm encourages investors who acquired Intellia stock during the class period to contact them for further information and support.
Read more →NTLA▼ -5.6%on this newsshared move
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
Intellia Therapeutics, a leader in gene editing, will hold a conference call on August 7, 2025, to discuss its second quarter earnings and operational updates. This event highlights the company's commitment to advancing CRISPR-based therapies. Investors and interested parties can participate through a live webcast or by dialing in to the call. A replay of the call will be available later on the company's website.
Read more →NTLA▲ +7.8%on this news
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congr
Intellia Therapeutics has reported promising three-year data from its Phase 1 study of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). Patients experienced a remarkable 98% reduction in monthly HAE attacks and remained attack-free for nearly two years post-treatment. The ongoing Phase 3 HAELO trial is set to provide further outcomes in 2026, with hopes for a U.S. launch in 2027. The data suggests lonvo-z could significantly improve patient quality of life by offering a durable and one-time treatment option.
Read more →NTLAINTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Intellia Therapeutics, Inc. following a class action complaint filed on February 11, 2025. The investigation focuses on potential breaches of fiduciary duties by the company's board of directors related to the Phase 1/2 study of NTLA-3001. Recently, Intellia announced the halting of all NTLA-3001 research and a significant workforce reduction after disclosing a shift in focus away from viral-based editing methods. Consequently, Intellia's stock saw a notable decline post-announcement.
Read more →NTLA▲ +6.6%on this news
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society
Intellia Therapeutics announced positive two-year follow-up data from the ongoing Phase 1 trial of Nexiguran Ziclumeran (nex-z) for hereditary ATTR amyloidosis with polyneuropathy during the Peripheral Nerve Society Annual Meeting. The results indicate that a single dose of nex-z resulted in significant reductions in serum TTR levels, leading to disease stability or improved neuropathic measures. This data also highlights the potential benefits for patients who previously experienced progression on alternative treatments.
Read more →NTLA▲ +13.6%on this news
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress • On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the
Intellia Therapeutics reported its financial results for the first quarter of 2025, highlighting progress in its clinical studies for hereditary angioedema and ATTR amyloidosis. The company is on track to complete enrollment in the Phase 3 HAELO study and has initiated patient dosing in MAGNITUDE-2 for ATTR with polyneuropathy. Despite a net loss increase, Intellia maintains a strong cash position, expected to fund operations through mid-2027. The company plans to present additional data at upcoming medical congresses in 2025.
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates
Intellia Therapeutics, a prominent gene editing firm, is scheduled to hold a conference call on May 8, 2025, to discuss its first quarter 2025 financial results and operational updates. Participants can join the call via U.S. or international dial-in numbers, and a live webcast will also be available. The call will provide insights into the company's progress and future directions in gene editing.
Read more →NTLAIntellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – NTLA
Intellia Therapeutics, Inc. is facing a class action lawsuit from investors who purchased shares between July 30, 2024, and January 8, 2025. The lawsuit alleges that the company failed to disclose crucial information regarding its Phase 1/2 study for NTLA-3001, including a drop in demand for viral-based editing technologies. Following an announcement that the research on NTLA-3001 would be halted and a workforce reduction of 27% would take place, the company's stock price saw a significant decline. Shareholders are advised to register for potential recovery options.
Read more →NTLA▲ +9.5%on this newsshared move
Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion
Intellia Therapeutics is facing a class action lawsuit related to its recently announced NTLA-3001 therapy for alpha-1 antitrypsin deficiency-associated lung disease. The lawsuit claims that the company made false statements about the viability and timelines of the drug's development, leading to a significant stock price decline after the announcement of a reorganization and discontinuation of NTLA-3001. Investors affected by the drop have until April 14, 2025, to file a lead plaintiff motion as advised by the Portnoy Law Firm.
Read more →NTLAIntellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 14, 2025 Deadline to file Lead Plaintiff Motion
Intellia Therapeutics, Inc. is facing a class action lawsuit initiated by the Portnoy Law Firm for investors who acquired shares between July 30, 2024, and January 8, 2025. The lawsuit claims that Intellia made false statements regarding the development of its drug NTLA-3001, which is intended to treat alpha-1 antitrypsin deficiency. Following a company reorganization and the decision to discontinue NTLA-3001's development, Intellia's stock price dropped significantly. Investors have a deadline of April 14, 2025, to file a lead plaintiff motion.
Read more →NTLAIntellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – NTLA
Intellia Therapeutics, Inc. is facing a class action securities lawsuit from injured investors that centers around allegations of securities fraud. This lawsuit pertains to information regarding the company's Phase 1/2 study of NTLA-3001, which has now been stopped due to declining demand for viral-based editing technologies. Following the announcement of this discontinuation and a planned workforce reduction of 27%, Intellia's stock price fell sharply. Investors affected by this situation have a deadline to participate in the lawsuit by April 14, 2025.
Read more →NTLA▼ -5.6%on this newsshared move
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Intellia Therapeutics has announced the first patient dosed in the MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) for treating hereditary ATTR amyloidosis with polyneuropathy. This advancement indicates strong potential for nex-z as a one-time gene editing treatment aiming to halt or reverse disease progression. The trial follows encouraging Phase 1 results, showing significant reductions in serum TTR levels. A biologics licensing application for ATTRv-PN is expected to be submitted by 2028.
Read more →NTLA▼ -6.4%on this newsshared move
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Intellia Therapeutics, Inc. Investors of Upcoming Deadline
Bernstein Liebhard LLP has issued a reminder for investors in Intellia Therapeutics, Inc. (NASDAQ: NTLA) regarding an upcoming deadline related to a securities fraud class action lawsuit. This lawsuit pertains to allegations of misrepresentation by the company concerning its Phase 1/2 study of NTLA-3001 for treating AATD-associated lung disease. Investors who purchased shares between July 30, 2024, and January 8, 2025, are urged to be aware of their legal rights. Legal representation is available on a contingency fee basis.
Read more →NTLAIntellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion.
The Portnoy Law Firm has announced a class action lawsuit for Intellia Therapeutics investors who purchased securities between July 30, 2024, and January 8, 2025. Investors have until April 14, 2025, to file a lead plaintiff motion. The complaint alleges that Intellia made misleading statements about the viability of its NTLA-3001 treatment, which resulted in a significant stock price drop following a company reorganization that deprioritized this drug. Key concerns include the high costs and inefficiencies associated with viral-based editing technologies.
Read more →NTLAIntellia Therapeutics, Inc. Shareholders are Reminded of the Lead Plaintiff Deadline – Contact Robbins LLP for Information on How to Lead the Class Action Against NTLA
Intellia Therapeutics, Inc. is facing a class action lawsuit filed by Robbins LLP on behalf of investors who acquired NTLA securities between June 30, 2024, and January 28, 2025. The allegations involve misleading investors about the progress and viability of the Phase 1/2 study of their drug candidate NTLA-3001 for treating lung disease associated with alpha-1 antitrypsin deficiency. The company recently announced a halt to NTLA-3001 research and a workforce reduction of 27%, which contributed to a 15% decline in stock price. Shareholders are encouraged to contact Robbins LLP for participation in the class action.
Read more →NTLAIntellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
Intellia Therapeutics announced that its investigational therapy, nexiguran ziclumeran (nex-z), has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). This designation aims to expedite the development and review of potential treatments for serious conditions. Interim Phase 1 data has demonstrated significant reductions in serum TTR levels after a single dose of nex-z, highlighting its transformative potential. Intellia has also received Orphan Drug Designation for nex-z from the FDA and European Commission.
Read more →NTLAIntellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress - Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedem
Intellia Therapeutics has reported its fourth quarter and full-year financial results for 2024, highlighting key progress across its clinical programs. The company has commenced dosing patients in the global Phase 3 HAELO study for its investigational therapy NTLA-2002 targeting hereditary angioedema. Additionally, enrollment in its pivotal MAGNITUDE trial for the treatment of transthyretin amyloidosis (ATTR) is ahead of schedule, with a significant number of patients expected to be enrolled by year end. However, the company also announced a strategic review resulting in workforce reductions and the discontinuation of certain programs.
Read more →NTLAIntellia Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA
Intellia Therapeutics, Inc. is facing a class-action lawsuit based on alleged securities law violations linked to their NTLA-3001 program. During the period from July 30, 2024, to January 8, 2025, the lawsuit claims that the company failed to disclose critical information regarding the declining demand for viral-based gene editing methods. On January 9, 2025, Intellia announced the cessation of all NTLA-3001 research and a 27% workforce reduction, triggering a drop in its stock price. Investors affected by these developments have a deadline of April 14, 2025, to seek lead plaintiff status in the lawsuit.
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates
Intellia Therapeutics is set to hold a conference call on February 27, 2025, to discuss its fourth quarter and full-year 2024 earnings as well as operational highlights. This call is part of their ongoing communication with investors and stakeholders. Interested participants can join via phone or through a live webcast. Following the call, a replay will be available on their website.
Read more →NTLA▲ +7.8%on this newsshared move
INTELLIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Intellia Therapeutics, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Intellia Therapeutics, Inc. on behalf of investors who acquired its securities during a specified class period. The lawsuit claims that Intellia misled investors regarding the Phase 1/2 study of NTLA-3001. Following the revelation that Intellia would cease research on this drug and implement a significant workforce reduction, the company's stock price fell sharply. Investors are encouraged to contact the law firm for more information on their rights and potential claims.
Read more →NTLA▲ +11%on this news· ran to +27% by day 3shared move
Intellia Therapeutics, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against NTLA
A class action has been filed against Intellia Therapeutics, Inc. (NTLA) on behalf of investors who purchased shares from June 30, 2024, to January 28, 2025. The lawsuit alleges that Intellia misled investors regarding the viability of its drug candidate NTLA-3001 for treating AATD-associated lung disease. The complaint cites a lack of disclosure about declining demand for viral-based editing technologies and the subsequent decision to halt NTLA-3001 research, which led to a significant drop in share price. Robbins LLP is leading the class action and is inviting shareholders to participate as lead plaintiffs.
Read more →NTLAINTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) INVESTOR ALERT: Investors With Large Losses in Intellia Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Bernstein Liebhard LLP has announced a class action lawsuit on behalf of investors in Intellia Therapeutics, Inc. who purchased shares from July 30, 2024, to January 8, 2025. The lawsuit alleges that the defendants made misrepresentations about Intellia's clinical trial for NTLA-3001, which is aimed at treating alpha-1 antitrypsin deficiency-related lung disease. Investors are encouraged to participate as class members, with a lead plaintiff to be appointed by April 14, 2025. The law firm has a long history of successful litigations, having recovered over $3.5 billion for its clients.
Read more →NTLA▲ +10.8%on this news
Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
Intellia Therapeutics announced that the first patient was dosed in the global Phase 3 HAELO study of NTLA-2002, a CRISPR gene editing therapy for hereditary angioedema. The trial aims to assess the efficacy and safety of NTLA-2002, with plans to complete patient enrollment by late 2025 and submit a biologics license application in 2026. There is optimism surrounding the potential for NTLA-2002 to provide long-term relief from the disease. The pivotal trial will evaluate the treatment in a double-blind, placebo-controlled manner, focusing on patients with Type I or Type II HAE.
Read more →NTLA▼ -15.1%on this news
Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z) Priority programs NTLA-2002 fo
Intellia Therapeutics has announced strategic priorities and key milestones for 2025, focusing on the development of its late-stage programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z). The company is experiencing strong momentum with three Phase 3 pivotal studies actively enrolling patients. CEO John Leonard emphasized the potential of these programs to meet significant unmet needs in hereditary angioedema (HAE) and transthyretin amyloidosis (ATTR). The strategic reorganization is intended to concentrate resources where the company sees the most opportunity for value creation in a challenging market environment.
Read more →NTLAIntellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Intellia Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its investigational gene-editing therapy, nexiguran ziclumeran (nex-z), aimed at treating hereditary transthyretin amyloidosis with polyneuropathy. This designation, which highlights the transformative potential of nex-z, follows encouraging interim Phase 1 clinical trial results indicating significant reductions in TTR protein levels. Nex-z represents a pioneering effort as a one-time treatment for this serious condition, with additional regulatory designations having been previously awarded. Intellia is collaborating with Regeneron for the development and commercialization of this therapy.
Read more →NTLAIntellia Announces First Clinical Evidence from Ongoing Phase 1 Study that nexiguran ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR)
Intellia Therapeutics provided positive results from its ongoing Phase 1 trial of nexiguran ziclumeran (nex-z), a CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis. The presented data indicates that the treatment may favorably affect disease progression, showing significant TTR reduction and improvement in cardiac disease markers. These findings were shared at the 2024 AHA Scientific Sessions and published in a notable medical journal, enhancing their significance. Additionally, Intellia's confidence in the efficacy of their upcoming Phase 3 studies has increased based on the trial outcomes.
Read more →NTLAIntellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z)
Intellia Therapeutics reported strong third quarter 2024 financial results, revealing several advancements in its gene editing pipeline. The company received IND clearance from the U.S. FDA to initiate its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran in hereditary transthyretin amyloidosis with polyneuropathy. In addition, Intellia showcased impressive patient enrollment in ongoing trials and plans to present new clinical data at the upcoming 2024 American Heart Association Scientific Sessions. Their financial stability is underscored by a cash position of approximately $945 million.
Read more →NTLAIntellia Therapeutics Announces Two Upcoming Investor Events in November 2024
Intellia Therapeutics announced two virtual investor events taking place in November 2024. The first event will cover the company's third quarter financial results on November 7, while the second aims to present new clinical data from the ongoing Phase 1 study of nexiguran ziclumeran (nex-z) on November 16. The latter presentation aligns with a late-breaking session at the upcoming AHA Scientific Sessions. Intellia continues to focus on advancing its CRISPR-based gene editing therapies.
Read more →NTLA▼ -20.5%on this news
Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Intellia Therapeutics has reported positive Phase 2 results for NTLA-2002, a CRISPR-based gene editing treatment for hereditary angioedema (HAE). The data suggests that a majority of patients experienced a complete response with no further attacks after a single infusion. These findings could transform the current treatment approach for HAE, which typically requires chronic therapy. The investigational therapy is now set for evaluation in a pivotal Phase 3 study, marking a significant step forward for patients suffering from this genetic condition.
Read more →NTLAIntellia Therapeutics Announces New Date for Upcoming Investor Webcast
Intellia Therapeutics, Inc. has rescheduled its investor webcast for discussing the Phase 2 data of NTLA-2002 to October 24 at 8:30 a.m. ET. The company remains committed to its planned presentation at the ACAAI Annual Scientific Meeting, which coincides with the new webcast date. NTLA-2002 targets hereditary angioedema by inactivating the KLKB1 gene to prevent attacks, and has received multiple regulatory recognitions. Previous Phase 1 data has indicated substantial promise for this therapy.
Read more →NTLAIntellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Intellia Therapeutics has initiated the HAELO Phase 3 study of NTLA-2002, a gene editing treatment for hereditary angioedema (HAE). This single-dose therapy aims to prevent life-threatening swelling attacks, and it has shown promising results in preliminary trials, including substantial reductions in attack frequency. The pivotal study will enroll 60 adults and assess the efficacy and safety of NTLA-2002 compared to placebo. Positive regulatory feedback has been received, supporting the advancement of this investigational therapy.
Read more →NTLA▼ -6.6%on this newsshared move
Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
Intellia Therapeutics announced that it will present new interim data from its Phase 1 study of nexiguran ziclumeran (nex-z) at the 2024 AHA Scientific Sessions. Nex-z, an investigational gene editing therapy, aims to provide a single-dose treatment for transthyretin (ATTR) amyloidosis. The presentation will cover safety results and biomarkers of disease progression in patients with ATTR amyloidosis with cardiomyopathy. The event is scheduled for November 16-18, 2024, in Chicago, Illinois.
Read more →NTLAIntellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
Intellia Therapeutics announced the upcoming presentation of detailed data from the Phase 2 study of its investigational gene editing therapy NTLA-2002 for hereditary angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting. This presentation follows a previous positive topline announcement that the trial met all primary and secondary endpoints. NTLA-2002 is a single-dose treatment leveraging CRISPR technology, aiming to provide a one-time solution for HAE, which currently lacks a cure. The investor webcast to review the new data will take place on October 28, 2024.
Read more →NTLA▲ +5%on this news
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress - Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan
Intellia Therapeutics announced positive results for its Phase 2 study of NTLA-2002, which met all primary and secondary endpoints for hereditary angioedema. The company is preparing to initiate a pivotal Phase 3 trial with the selected 50 mg dose in the second half of 2024. Additionally, Intellia is rapidly enrolling in ongoing Phase 3 trials for NTLA-2001, targeting ATTR amyloidosis, and is on track to commence other clinical studies later this year. The company reported a robust financial standing, ending Q2 2024 with about $940 million in cash.
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates
Intellia Therapeutics, a clinical-stage gene editing company, will hold a conference call on August 8, 2024, at 8 a.m. ET to present its second quarter 2024 financial results and operational highlights. This event demonstrates the company's focus on sharing critical business updates with stakeholders. Attendees can join via dial-in or a live webcast, with a replay available later on Intellia’s website. The announcement reflects Intellia's ongoing commitment to advancing its CRISPR-based therapies and enhancing investor relations.
Read more →NTLAIntellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency
Intellia Therapeutics has received regulatory authorization from the UK’s MHRA to initiate a Phase 1/2 clinical trial for NTLA-3001, a potential gene editing treatment for alpha-1 antitrypsin deficiency (AATD). The therapy aims to restore AAT protein levels with a single dose, potentially improving patient outcomes significantly. The study will involve up to 30 patients and includes a phase for dose escalation and expansion. Intellia plans to submit additional regulatory applications in other jurisdictions as part of its global development strategy.
Read more →NTLAIntellia Therapeutics Announces CFO Transition
Intellia Therapeutics has announced the appointment of Edward Dulac as the new Chief Financial Officer, effective July 22, 2024. Dulac brings over 20 years of experience in finance and corporate strategy, previously serving as CFO at Fate Therapeutics and holding various positions at Celgene. The CEO of Intellia, John Leonard, expressed confidence in Dulac's ability to support the company’s mission in developing CRISPR-based therapies. Glenn Goddard, the outgoing CFO, will step down on June 30, 2024.
Read more →NTLAIntellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
Intellia Therapeutics reported positive results from the ongoing Phase 1 study of its CRISPR-based therapy, NTLA-2001, showcasing the potential for redosing to achieve a median 90% reduction in serum TTR levels. Although redosing is not currently planned for the ongoing ATTR amyloidosis program, this clinical data offers a significant advancement that may allow for greater flexibility in treating various conditions. The study indicated strong safety and tolerability profiles, which supports the future direction of Intellia's non-viral delivery platform. These results were presented at the Peripheral Nerve Society Annual Meeting, highlighting a novel approach in gene editing treatments.
Read more →NTLAIntellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024
Intellia Therapeutics (NTLA) announced that it will present data on redosing from the Phase 1 study of NTLA-2001 at the Peripheral Nerve Society Annual Meeting in June 2024. This presentation will mark the first-ever clinical data involving redosing with an in vivo CRISPR-based gene editing therapy. NTLA-2001 aims to provide a one-time treatment for transthyretin amyloidosis, showing promising interim results in reducing TTR levels. While repeat dosing isn't part of the current treatment plan, it suggests future potential for therapies employing similar delivery methods.
Read more →NTLAIntellia Therapeutics Names Brian Goff to its Board of Directors
Intellia Therapeutics has appointed Brian Goff to its board of directors, aiming to leverage his extensive commercialization experience to enhance its transition from clinical development to commercialization. Goff, who has led successful rare disease product launches, is expected to guide the company as it prepares to introduce its CRISPR-based gene editing therapies. This strategic addition highlights Intellia's commitment to leading in the evolving landscape of gene editing medicine.
Read more →NTLA▲ +10%on this news
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Intellia Therapeutics has announced promising long-term data from its Phase 1 study of NTLA-2002, a CRISPR-based gene editing therapy for hereditary angioedema (HAE). The data reveals that eight out of ten patients have remained attack-free for over 18 months, along with a reported 98% reduction in monthly attack rates. Patients also exhibited a favorable safety profile with no serious adverse events recorded. The findings were presented at the EAACI Congress 2024, with future plans for a pivotal Phase 3 trial expected later this year.
Read more →NTLA▲ +8.1%on this news
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress - Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATT
Intellia Therapeutics announced its financial results for the first quarter of 2024, highlighting significant progress in its clinical development pipeline. The company is rapidly enrolling patients in the Phase 3 MAGNITUDE trial for NTLA-2001 aimed at treating ATTR amyloidosis with cardiomyopathy. Additionally, they plan to initiate a new Phase 3 trial for hereditary ATTR amyloidosis with polyneuropathy by year-end, following alignment with the FDA. Intellia's robust cash position stands at approximately $953 million, providing a stable foundation for ongoing and future studies.
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
Intellia Therapeutics plans to hold a conference call on May 9, 2024, at 8 a.m. ET to discuss its first quarter 2024 financial results and operational highlights. U.S. and international callers can participate by dialing designated numbers. A replay of the call will be available on the company's website later that day. Intellia focuses on revolutionizing medicine through CRISPR-based therapies, using both in vivo and ex vivo gene editing techniques.
Read more →NTLA▲ +5.9%on this newsshared move
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
Intellia Therapeutics announced it will present updated data from its Phase 1/2 study of NTLA-2002, a CRISPR-based gene editing therapy for hereditary angioedema, at the EAACI Congress 2024. The presentation will include vital information on safety, kallikrein reduction, and the rate of patient attacks, underlining progress in the trial. NTLA-2002 aims to be a groundbreaking one-time treatment for a condition traditionally managed with lifelong therapies. A subsequent investor webcast is also scheduled to discuss the findings further.
Read more →NTLA▼ -5.6%on this news
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine - Data reinforce the potential of NTLA-2002 to elim
Intellia Therapeutics announced the publication of positive interim Phase 1 data for its investigational therapy NTLA-2002, aimed at treating hereditary angioedema (HAE). The data, published in the New England Journal of Medicine, highlight a 95% mean reduction in monthly HAE attack rates, with most patients remaining attack-free following treatment. The therapy was well tolerated, demonstrating only mild side effects. Intellia plans to initiate a pivotal Phase 3 study for NTLA-2002 in late 2024, contingent upon regulatory feedback.
Read more →NTLAIntellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
Intellia Therapeutics has announced the dosing of the first patient in the Phase 3 MAGNITUDE trial for NTLA-2001, a CRISPR-based treatment for transthyretin (ATTR) amyloidosis with cardiomyopathy. This trial aims to evaluate the efficacy and safety of NTLA-2001, following promising results from earlier Phase 1 trials. With multiple trial sites enrolling patients, there is significant enthusiasm in the ATTR amyloidosis community for this potential one-time gene editing therapy. The trial's outcome could lead to future marketing applications for this revolutionary treatment.
Read more →NTLAAMENDMENT NO. 1
Intellia Therapeutics, Inc. has executed Amendment No. 1 to the Open Market Sale Agreement with Jefferies LLC. This amendment updates specific terms of the original agreement dated March 4, 2022, including adjustments to financial references and contact information. The company is also required to file a Prospectus Supplement reflecting these changes within two business days. The agreement will continue to be governed by New York law.
Read more →NTLAIntellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress - On track to dose the first patient in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatmen
Intellia Therapeutics has announced its fourth-quarter and full-year 2023 financial results, highlighting significant progress in its programs. The company is on track to begin the Phase 3 MAGNITUDE trial for NTLA-2001 in Q1 2024 and plans to initiate the Phase 3 study for NTLA-2002 by the second half of 2024. Recent positive interim results from a Phase 1 study of NTLA-2002 were published, and Intellia ended 2023 with a robust cash position of approximately $1.0 billion. However, the company faced a decrease in collaboration revenue and high operational costs.
Read more →NTLAIntellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
Intellia Therapeutics and ReCode Therapeutics have announced a strategic collaboration focused on developing novel gene editing therapies for cystic fibrosis. By integrating Intellia's CRISPR-based platform and ReCode's Selective Organ Targeting lipid nanoparticle technology, the partnership aims to address genetic mutations causing cystic fibrosis, particularly for patients who lack treatment options. Intellia will design the editing strategies and research-grade components, while ReCode will oversee preclinical and clinical development as well as commercialization of certain programs. This collaboration marks a significant step toward improving treatment options for cystic fibrosis patients.
Read more →NTLA▲ +6.9%on this newsshared move
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
Intellia Therapeutics, Inc. is set to hold a conference call on February 22, 2024, to discuss its fourth quarter and full-year 2023 financial results and operational highlights. The call will provide insights into the company's progress in gene editing and CRISPR-based therapies. Intellia continues to focus on expanding its innovative capabilities within the field of gene editing, aiming to revolutionize treatment methods.
Read more →NTLAIntellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones Core priorities through 2026 include completion of Phase 3 study and BLA submission for NTLA-2002, completion of pa
Intellia Therapeutics announced its strategic priorities extending through 2026, focusing on advancing its investigational therapies, particularly NTLA-2001 for transthyretin amyloidosis. The company expects to achieve key milestones in 2024, including participation in the J.P. Morgan Healthcare Conference and significant developments in clinical trials. Intellia is dedicated to improving its gene editing capabilities, with plans to expand treatments beyond liver-dominant diseases. However, risks related to regulatory approvals and financial stability could pose challenges ahead.
Read more →NTLA▲ +11.1%on this news
Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
Intellia Therapeutics has received European Union orphan drug designation for NTLA-2002, an investigational CRISPR genome editing treatment aimed at hereditary angioedema (HAE). This designation allows for regulatory and commercial incentives as Intellia moves forward with the clinical development of NTLA-2002. The company is on track to complete enrollment for the Phase 2 portion of their clinical study soon, which is critical for advancing their efforts to deliver a one-time treatment option for HAE patients. NTLA-2002 represents a novel approach, exciting the potential for significant improvements in patient care.
Read more →NTLA▼ -12.3%on this newsshared move
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress - FDA cleared NTLA-2001 IND application for first in vivo CRISPR candidate to enter late-stage clinical developm
Intellia Therapeutics reported positive advancements during its third quarter of 2023, including FDA clearance of the NTLA-2001 IND application for late-stage clinical development and promising Phase 1 clinical trial data. The company is preparing to initiate a pivotal Phase 3 trial for NTLA-2001 by the end of the year while making progress in its NTLA-2002 Phase 2 study for hereditary angioedema. Additionally, Intellia is on track to submit a Clinical Trial Application for NTLA-3001 in early 2024, marking significant strides in its CRISPR gene-editing therapy pipeline. The company ended the quarter with a robust financial outlook, holding approximately $992.5 million in cash.
Read more →NTLAIntellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4 th International ATTR Amyloidosis Meeting Updated data from over 60 patients showed consistent, deep and durable serum TTR reduction
Intellia Therapeutics presented new interim results from its Phase 1 study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting. The study demonstrated significant serum TTR reductions across a large dataset of over 60 patients, suggesting a potential new standard of care for treating ATTR amyloidosis. NTLA-2001, an investigational CRISPR-based gene editing therapy, shows promise as a single-dose treatment. The trial has concluded enrollment, and safety data indicates the treatment was well tolerated with no serious adverse effects noted.
Read more →NTLAIntellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November
Intellia Therapeutics is set to present updated data on NTLA-2001, its treatment for transthyretin (ATTR) amyloidosis, at the 4th International ATTR Amyloidosis Meeting on November 2, 2023. This presentation will include safety assessments and serum TTR reduction results from the ongoing Phase 1 study. Additionally, the company will discuss this data during their third quarter earnings call on November 9, 2023, outlining the upcoming Phase 3 study design.
Read more →NTLAIntellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy NTLA-
Intellia Therapeutics has received FDA clearance for its Investigational New Drug application for NTLA-2001, a therapy targeting transthyretin amyloidosis with cardiomyopathy. The upcoming pivotal Phase 3 trial is set to begin by the end of 2023, marking a significant advancement in the use of CRISPR technology in clinical settings. NTLA-2001 aims to establish a new standard of care for this condition, potentially offering patients a single-dose solution. This development reflects Intellia's commitment to improving therapeutic options in the field of gene editing.
Read more →NTLAIntellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
Intellia Therapeutics announced that the European Medicines Agency has granted its investigational therapy NTLA-2002 Priority Medicine (PRIME) designation for hereditary angioedema. This designation comes after promising interim results from a Phase 1 study, where NTLA-2002 demonstrated a 95% mean reduction in attack rates. The therapy utilizes CRISPR technology for genome editing, positioning it as a potentially curative option for patients. The FDA has also granted NTLA-2002 several special designations, emphasizing its innovative approach to treating this rare genetic disorder.
Read more →NTLARegeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases Collaboration combines Intellia s leading genome editing platform,
Regeneron Pharmaceuticals and Intellia Therapeutics announced an expanded collaboration to develop CRISPR-based therapies targeting neurological and muscular diseases. This partnership will leverage Regeneron's proprietary AAV delivery systems and Intellia's Nme2 CRISPR/Cas9 editing technology. The companies plan to research two non-liver in vivo targets initially, with an opportunity for co-development of product candidates. This collaboration represents an advancement in gene editing capabilities, aiming to address significant medical needs.
Read more →NTLAIntellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress - Completed identification of all patients for the Phase 2 study of NTLA-2002 for the treatment of hereditary a
Intellia Therapeutics announced positive developments in their pipeline during the second quarter of 2023, including the completion of patient identification for the Phase 2 study of NTLA-2002 for hereditary angioedema. A global pivotal Phase 3 study for this treatment is planned to commence as early as Q3 2024, pending regulatory feedback. The company is also in the process of submitting an IND application for NTLA-2001 targeting ATTR amyloidosis, with expectations to initiate studies by the end of the year. Intellia's financial standing is robust, boasting around $1.1 billion in cash to support ongoing research efforts.
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates
Intellia Therapeutics, a clinical-stage genome editing company, will hold a conference call on August 3, 2023, to discuss its financial results for the second quarter of 2023. The call will take place at 8 a.m. ET, with specific dial-in numbers provided for U.S. and international participants. A live webcast will also be available for those wishing to attend virtually. Additionally, a replay of the call will be accessible on Intellia's website following the event.
Read more →NTLAIntellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE) Extended Phase 1 data reinforce the p
Intellia Therapeutics announced updated interim results from the Phase 1 study of NTLA-2002, a CRISPR-based treatment for hereditary angioedema (HAE). The data revealed up to a 95% reduction in monthly HAE attack rates among participants, with some remaining attack-free for over a year. The treatment proved well-tolerated, with a favorable safety profile and mild adverse events. The Phase 2 portion of the clinical trial is currently ongoing.
Read more →NTLAIntellia Therapeutics Announces Retirement of Jean-Fran ois Formela, M.D. from Its Board of Directors
Intellia Therapeutics announced the retirement of Jean-Fran ois Formela, M.D. from its board of directors, effective June 15, 2023. Dr. Formela, a co-founder of Intellia, has served on the board since May 2014 and has been instrumental in advancing the company's CRISPR-based therapies. The company expressed gratitude for his vision and leadership, while emphasizing confidence in its future under the current management team. This transition comes as Intellia continues to focus on innovative approaches to genome editing.
Read more →NTLAIntellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023
Intellia Therapeutics has announced the acceptance of a late-breaking abstract for presentation at the EAACI Hybrid Congress 2023, focusing on its NTLA-2002 clinical study for hereditary angioedema. The updated data will cover safety, kallikrein reduction, and HAE attack rates across all dose cohorts from the Phase 1 trial. A live investor webcast is scheduled for June 12, where additional insights on the data and overall treatment landscape for HAE will be discussed. The study aims to assess the long-term effects of NTLA-2002, a CRISPR-based therapy targeting the KLKB1 gene.
Read more →NTLA▲ +13.1%on this news
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress - Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)
Intellia Therapeutics has reported its first-quarter financial results and marked significant progress in its clinical programs. The company announced the dosing of the first patient in the global Phase 2 study of NTLA-2002 for hereditary angioedema. Additionally, Intellia expects to submit an IND application for NTLA-2001 targeted at ATTR amyloidosis within the year. The company's financial health remains robust with $1.2 billion in cash, allowing for continued investment in promising therapies.
Read more →NTLAIntellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities
Intellia Therapeutics has released its 2023 Corporate Responsibility report, showcasing advancements in its Environmental, Social, and Governance (ESG) priorities. The report emphasizes the company's commitment to developing curative genome editing therapies, supporting employee growth, and engaging with local communities. Additionally, Intellia highlights its commitment to cybersecurity and corporate governance, ensuring long-term shareholder benefit. This marks the first time the company aligns its ESG disclosure with the Sustainability Accounting Standards Board framework, enhancing transparency in its corporate practices.
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates
Intellia Therapeutics, a prominent player in genome editing, has announced a conference call scheduled for May 4, 2023, to discuss its financial results for the first quarter of 2023 and provide operational updates. The call is intended for investors and stakeholders to gain insight into the company's performance and future direction. Callers can access the event through dedicated phone numbers and a live webcast, with a replay available afterward on Intellia's website.
Read more →NTLAIntellia Therapeutics Names Bill Chase to its Board of Directors
Intellia Therapeutics has appointed Bill Chase to its Board of Directors, with plans to succeed Caroline Dorsa as chair of the audit committee upon her retirement. Chase brings over three decades of financial and strategic management experience from his roles at AbbVie and Abbott Laboratories. The leadership change aims to strengthen the board's capabilities in guiding Intellia's advancement of genomic medicine initiatives. Dorsa's departure is due to her appointment as chair at Biogen.
Read more →NTLAIntellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema
Intellia Therapeutics has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational therapy NTLA-2002, aimed at treating hereditary angioedema (HAE). This designation recognizes the potential of the therapy to address serious unmet medical needs and could expedite its development process. The ongoing Phase 1/2 study has shown positive interim results, demonstrating reductions in plasma kallikrein and HAE attacks. NTLA-2002 represents an innovative CRISPR-based approach, marking a significant advancement in the treatment of HAE.
Read more →NTLA▲ +8%on this news
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Theapy for the Treatment of Hereditary Angioedema (HAE) - NTLA-2002 is a
Intellia Therapeutics has received FDA clearance for its Investigational New Drug application for NTLA-2002, an in vivo CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This approval allows the inclusion of the U.S. in the global Phase 2 study of NTLA-2002, which seeks to permanently reduce the activity of the kallikrein B1 gene after a single dose. The company has reported encouraging early results from the Phase 1 study, demonstrating significant reductions in HAE attack rates. The Phase 2 study is currently underway, with patient screening initiated outside the U.S.
Read more →NTLAIntellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress - Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatmen
Intellia Therapeutics announced its financial results for the fourth quarter and full year of 2022, highlighting significant progress in its ongoing clinical programs. The company initiated a global Phase 2 study of NTLA-2002 for hereditary angioedema and submitted an IND application for inclusion of U.S. patients. Intellia's ongoing studies for NTLA-2001 and NTLA-3001 are set to advance in 2023, with plans for additional clinical data presentations. The company maintains a strong financial position with $1.3 billion in cash, supporting its future endeavors.
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates
Intellia Therapeutics, a clinical-stage genome editing firm, will host a conference call on February 23, 2023, to discuss its fourth-quarter and full-year 2022 financial results alongside operational updates. The call is set for 8 a.m. ET, with details on connecting provided for U.S. and international callers. A replay of the call will be accessible later on the company's website.
Read more →NTLAIntellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
Intellia Therapeutics has been awarded the Innovation Passport for its investigational genome editing treatment, NTLA-2002, aimed at hereditary angioedema (HAE). This designation facilitates entry into the U.K.'s Innovative Licensing and Access Pathway, allowing for expedited development and patient access to innovative therapies. The company plans to initiate the Phase 2 portion of the clinical study in the first half of 2023, building on the ongoing assessment of NTLA-2002's safety and efficacy.
Read more →NTLAIntellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones - Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and validate its i
Intellia Therapeutics outlined its strategic priorities for 2023, emphasizing the late-stage development of its CRISPR-based therapies, NTLA-2001 for ATTR amyloidosis and NTLA-2002 for hereditary angioedema. The company plans to submit IND applications for these therapies and initiate pivotal studies by the end of the year. Additionally, Intellia aims to progress its platform capabilities in gene editing and explore novel therapeutic approaches, maintaining a solid financial position with over $1.3 billion in cash. These steps mark the company's ambition to set new standards of care in treating serious diseases.
Read more →NTLA▲ +7.2%on this newsshared move
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that it has commenced an under
Read more →NTLAIntellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeti
Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting -Robust reductions in plasma kallikrein levels and HAE
Read more →NTLAIntellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Asso
Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022 -Data presented in late-br
Read more →NTLAIntellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress - Presented interim data from the cardiomyopathy arm of NTLA-2001 Phase 1 study demonstrating deep and sustained
Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress -Presented interim data from the cardiomyopathy arm of NTLA-2001 Phase 1 study demonstrating deep and sustained mean serum TTR reductions of 93% and 92% at 0.7 mg/kg and 1
Read more →NTLAIntellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting
CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that an abstract featuring
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its third quarter 2022 financi
Read more →NTLAIntellia Therapeutics to Present at October Healthcare Investor Conferences
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that members of its manage
Read more →NTLAIntellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis Interim data from th
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis CAMBRIDGE, Mass. and TARRYTOWN, N.Y., Sept. 16, 2022 Intellia Therapeutics, In
Read more →NTLAIntellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)
Positive interim clinical data further validate the modularity of Intellia’s industry-leading genome editing platform and its potential to target a multitude of genetic diseases A single dose of NTLA-2002 led to a 65% and 92% mean plasma kallikrein reduction at 25 mg and 75 mg d
Read more →NTLA▲ +6.5%on this news
Intellia Therapeutics Announces Upcoming Investor Event to Present Interim Clinical Data from Ongoing First-in-Human Studies of NTLA-2002 and NTLA-2001 on September 16, 2022
Review of first clinical data from ongoing Phase 1/2 Study of NTLA-2002 for the treatment of hereditary angioedema (HAE) presented at the 2022 Bradykinin Symposium Event to include interim safety and serum TTR reduction data from the cardiomyopathy arm of the Phase 1 study of NT
Read more →NTLAIntellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema
NTLA-2002, an in vivo genome editing candidate designed to prevent angioedema attacks in patients with hereditary angioedema (HAE) after a single dose, is currently being evaluated in a Phase 1/2 study CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, I
Read more →NTLA▲ +11.6%on this news
Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin Symposium
First clinical data on safety and activity of NTLA-2002, Intellia’s second systemically administered in vivo CRISPR candidate CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on
Read more →NTLA▼ -8.7%on this news
Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress - Completed dose-escalation portion of the ongoing Phase 1 study of NTLA-2001 in patients with transthyretin (A
Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress -Completed dose-escalation portion of the ongoing Phase 1 study of NTLA-2001 in patients with transthyretin (ATTR) amyloidosis with cardiomyopathy; expects to present int
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates
CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its second quarter 2022 financ
Read more →NTLA▲ +5.2%on this news
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose CAMBRIDGE, Mass. and TARRYTOWN, N.Y., June
Read more →NTLA▲ +8.1%on this news· ran to -19% by day 3
Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022
Oral presentation to include additional durability data from patients treated with NTLA-2001, the first-ever systemically administered in vivo CRISPR investigational therapy Presentation to include data supporting fixed dose selection in the ongoing single-dose expansion cohort
Read more →NTLA▼ -10.2%on this news· ran to -20% by day 3
Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress - Presented updated interim data from ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis wi
Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress -Presented updated interim data from ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy, demonstrating a single dose of NTLA-2001
Read more →NTLA▲ +5.3%on this newsshared move
Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to i
Read more →NTLA▲ +5.3%on this newsshared move
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference
Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading T cells and deployable for TCR-T and CAR-T cell therapy Findings support recent development candidate initiation of NTLA-6001, an investigational allogeneic CAR-T therapy, for the
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2022 financ
Read more →NTLAIntellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that the U.S. Food and Dru
Read more →NTLA▼ -19.2%on this news· ran to -34% by day 3
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia
NTLA-5001 is a novel investigational T cell receptor (TCR)-T cell therapy which leverages Intellia’s proprietary cell engineering platform NTLA-5001 targets Wilms’ Tumor 1 (WT1), an overexpressed intracellular antigen frequently found in acute myeloid leukemia (AML) and other he
Read more →NTLAIntellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Di
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein CAMBRIDGE, Mass. and TARRYTOWN, N.Y
Read more →NTLA▲ +9.3%on this news· ran to +20% by day 1shared move
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress - On track to present additional interim data from dose-escalation portion of the ongoing Phase 1
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress -On track to present additional interim data from dose-escalation portion of the ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis wit
Read more →NTLAIntellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies
State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapies New facility in Waltham, Massachusetts expected to be operational in 2024 CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Intellia Therap
Read more →NTLA▼ -5.7%on this news· ran to -16% by day 3shared move
Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022
Fourth quarter and full-year 2021 financial results – February 24, at 8:00 a.m. ET Updated interim clinical data from the ongoing Phase 1 study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis – February 28, at 4:30 p.m. ET CAMBRIDGE, Mass., Feb. 17, 2022 (GLO
Read more →NTLA▲ +9.1%on this newsshared move
Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer
Collaboration combines Intellia’s genome editing platform with ONK’s optimized natural killer (NK) cell therapy platform Intellia grants ONK non-exclusive rights to its ex vivo genome editing and LNP delivery technologies and exclusive rights to certain guide RNAs for up to five
Read more →NTLAIntellia Therapeutics Announces Acquisition of Rewrite Therapeutics - Rewrite Therapeutics proprietary and versatile DNA writing platform enables a range of novel genome editing strategies - Acquisition further expands I
Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics CAMBRIDGE, Mass., Feb. 3, 2022 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today
Read more →NTLAIntellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022 - Advance clinical development of NTLA-2001, a potential single-dose therapy for transthyretin (ATTR) amyloidosis; on
Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022 -Advance clinical development of NTLA-2001, a potential single-dose therapy for transthyretin (ATTR) amyloidosis; on track to present additional data from Phase 1 study in Q1 20
Read more →NTLA▼ -9%on this newsshared move
Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases
— Intellia grants Kyverna exclusive rights to its differentiated allogeneic cell engineering platform for the development of KYV-201, a next-generation CD19 CAR T-cell therapy to treat autoimmune diseases — — Kyverna to lead and fund preclinical and clinical development; Intelli
Read more →NTLA▼ -9%on this newsshared move
Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced that the company is scheduled to presen
Read more →NTLAIntellia Therapeutics Appoints Derek Hicks as Chief Business Officer
CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of Derek Hicks to a
Read more →NTLAIntellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced that the first patient
Read more →NTLAIntellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced today that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has approved a protocol amendment for the Company’s ongoing Phase 1 study of NTLA-2001
Read more →NTLAIntellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting
CAMBRIDGE, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the presentation of da
Read more →NTLAIntellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress - Initiated dosing of Cohort 4 in the ongoing Phase 1 study of NTLA-2001; data update from completed dose-escala
Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress Initiated dosing of Cohort 4 in the ongoing Phase 1 study of NTLA-2001; data update from completed dose-escalation (Part 1) and initiation of dose-expansion (Part 2) expec
Read more →NTLA▲ +5%on this news
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its third quarter 2021 fi
Read more →NTLAIntellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that the U.S. Food and
Read more →NTLAIntellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress
First preclinical data demonstrating Intellia’s allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatments Demonstrated lipid nanoparticle-based delivery as a more efficient multiplex gene editing approach for engineered cell therapies as
Read more →NTLAIntellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies dire
Read more →NTLAIntellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual Congress
First data highlighting proprietary allogeneic cell engineering platform designed to overcome immune rejection for the development of therapeutic candidates to treat a variety of cancer and autoimmune diseases New data on proprietary cell engineering process utilizing lipid nano
Read more →NTLAIntellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
NTLA-2002 is the first single-dose genome editing therapeutic candidate designed to prevent attacks in people living with HAE to enter clinical study NTLA-2002 is Intellia’s second in vivo CRISPR genome editing therapeutic candidate; program to leverage platform insights gained
Read more →NTLAIntellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at Chardan’s 5th Annual
Read more →NTLAIntellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering process for the treatment of cancer to enter clinical study NTLA-5001 targets Wilms’ Tumor 1 (WT1), an overexpressed intracellular antigen on many hematologic malignancies and solid tumors In
Read more →NTLAIntellia Therapeutics to Present at September Healthcare Investor Conferences
CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the following virtual
Read more →NTLA▲ +12.4%on this news
Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress - Established proof of concept for the Company's modular in vivo delivery platform with first-ever clinical dat
Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress CAMBRIDGE, Mass., Aug. 05, 2021 - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics u
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates
CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its second quarter 2021 f
Read more →NTLAIntellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock
CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today the closing of an unde
Read more →NTLAIntellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis First-ev
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis CAMBRIDGE, Mass. and TARRYTOWN, N.Y., June 26, 2021 Intellia Ther
Read more →NTLAIntellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary
CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of James Basta, J.D
Read more →NTLABlackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company Focus will be on Development of Allogeneic Universal CAR T-Cell Therapies for Immuno-oncology and Autoimmune Di
Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company Focus will be on Development of Allogeneic Universal CAR T-Cell Therapies for Immuno-oncology and Autoimmune Diseases - Blackstone Life Sciences Commits to an Active Rol
Read more →NTLAIntellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting
Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidate Late-breaking abstract selected for oral presentation on June 26 CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeu
Read more →NTLAIntellia Therapeutics Announces First Quarter 2021 Financial Results - Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloid
Intellia Therapeutics Announces First Quarter 2021 Financial Results CAMBRIDGE, Mass., May 6, 2021 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company Updates
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its first quarter 2021 financial result
Read more →NTLAIntellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting
- Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD) CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced the presentation of new dat
Read more →NTLAIntellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors
Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors CAMBRIDGE, Mass., April 12, 2021 - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo
Read more →NTLAIntellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that the European Commission (EC) ha
Read more →NTLAIntellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present the first preclinical data set on its novel cytosine deaminase base editor technology at the seventh Cold Spring Harbor Laboratory (CSHL) virtual scientific meeting on Nucl
Read more →NTLAIntellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium
- Demonstrates the promise of Intellia’s proprietary non-viral delivery system for in vivo genome editing of tissues outside the liver, with applications to inherited blood disorders such as sickle cell disease - Observed durable, multidose editing of whole bone marrow and hemat
Read more →NTLAIntellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results - Expects to report initial data from Phase 1 study of NTLA-2001, a potentially curative single-course therapy for transthyretin amyloid
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 techn
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company Updates
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its fourth quarter and full-year 2020 fi
Read more →NTLAIntellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021 - Continued advancement of global Phase 1 study of NTLA-2001, a potentially curative single-course therapy for transth
Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021 CAMBRIDGE, Mass., Jan. 7, 2021 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using
Read more →NTLAIntellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency
Demonstrates modularity of Intellia’s in vivo liver insertion technology to durably restore protein, compared to traditional gene therapy Single-course administration of genome editing system provides potentially curative approach to AAT deficiency CAMBRIDGE, Mass., Dec. 12, 20
Read more →NTLAIntellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual Meeting
Lead immuno-oncology development candidate NTLA-5001 shows high anti-tumor activity as promising cancer treatment in proof-of-concept mouse models of acute leukemias Proprietary process enhances tumor control in preclinical models and enables efficient, scalable genome editing a
Read more →NTLAIntellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today the closing of an underwritten public
Read more →NTLAIntellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments
Funding from the Bill & Melinda Gates Foundation to develop safe, scalable and accessible non-viral treatments for sickle cell patients CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that it has received a grant from the
Read more →NTLAIntellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis
NTLA-2001: First single-course therapy that potentially halts and reverses ATTR progression First-ever in vivo CRISPR treatment delivered intravenously to a patient CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that the
Read more →NTLAIntellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis NTLA-2001: First single-course therapy that potentially halts and
Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis NTLA-2001: First single-course therapy that potentially halts and reverses ATTR progression First-ever in vivo CRISPR treatment delivered
Read more →NTLAIntellia Therapeutics Announces Third Quarter 2020 Financial Results - On track to dose first patient by year-end with NTLA-2001 for the treatment of transthyretin amyloidosis (ATTR), following regulatory a
Intellia Therapeutics Announces Third Quarter 2020 Financial Results CAMBRIDGE, Mass., Nov. 5, 2020 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in viv
Read more →NTLAIntellia Therapeutics Announces Third Quarter 2020 Financial Results
On track to dose first patient by year-end with NTLA-2001 for the treatment of transthyretin amyloidosis (ATTR), following regulatory authorization to initiate Phase 1 clinical trial Anticipates submitting an IND or IND-equivalent for lead TCR-T cell therapy, NTLA-5001 for the t
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its third quarter 2020 financial results
Read more →NTLAIntellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)
NTLA-2001: First single-course therapy that potentially halts and reverses ATTR On track to dose first patient by year-end with a systemically delivered CRISPR/Cas9-based therapy CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), anno
Read more →NTLAIntellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR) NTLA-2001: First single-course therapy that potentially halts and reverses A
Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR) NTLA-2001: First single-course therapy that potentially halts and reverses ATTR On track to dose first patient by year-end with a systemically deli
Read more →NTLAIntellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology
CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Today, Jennifer Doudna, Ph.D., one of Intellia Therapeutics, Inc.’s scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry for the development of the CRISPR/Cas9 genome editing technology. Dr. Doudna shared the aw
Read more →NTLAIntellia Therapeutics Names John F. Crowley to Board of Directors
Intellia Therapeutics Names John F. Crowley to Board of Directors CAMBRIDGE, Mass., Oct. 5, 2020 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, has ap
Read more →NTLAIntellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment
In Vivo gene knockout and insertion data to be presented at OTS Annual Meeting highlight modularity of Intellia’s platform and potential for variety of single-course therapies, with company’s first systemic treatment (NTLA-2001) expected to enter the clinic by year-end Liver ins
Read more →NTLAIntellia Therapeutics to Present at Chardan’s Virtual 4th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at Chardan’s Virtual 4th Annual Genetic
Read more →NTLAIntellia Therapeutics to Present at Baird’s 2020 Virtual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at Baird’s 2020 Virtual Global Healthca
Read more →NTLAIntellia Therapeutics Announces Second Quarter 2020 Financial Results
Submitted first regulatory application to the U.K.’s MHRA to initiate a Phase 1 study of NTLA-2001 for the treatment of transthyretin amyloidosis; on track to dose first patient by year-end Expanded Regeneron collaboration, receiving $100 million through upfront cash and equity
Read more →NTLAIntellia Therapeutics Announces Second Quarter 2020 Financial Results - Submitted first regulatory application to the U.K.'s MHRA to initiate a Phase 1 study of NTLA-200 1 for the treatment of transthyretin
Intellia Therapeutics Announces Second Quarter 2020 Financial Results CAMBRIDGE, Mass., Aug. 6, 2020 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vi
Read more →NTLAIntellia Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the 2020 Wedbush PacGrow Healthcare V
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2020 Earnings and Company Updates
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its second quarter 2020 financial result
Read more →NTLAIntellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., June 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the closing of an underwritten public
Read more →NTLARegeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments - Regeneron and Intellia to co-develop potential hemophilia A and B treatments using their jointly-owned targ
Regeneron and Intellia Collaboration to Develop CRISPR/Cas9-Based Treatments Tarrytown, New York and Cambridge, Mass. June 1, 2020 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced an expansion of their existing collaborati
Read more →NTLAIntellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
Intellia’s CRISPR/Cas9 proprietary process produces multiple, highly efficient sequential edits in T cells that have superior function and minimal translocations, compared to results from standard T cell engineering approaches Proprietary process supports NTLA-5001 and other pot
Read more →NTLAIntellia Therapeutics Announces First Quarter 2020 Financial Results
On track to submit an IND or IND-equivalent for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020; plans to dose first patient in 2H 2020 On track to submit an IND or IND-equivalent for lead TCR-T cell therapy, NTLA-5001 for the treatment of acute myeloid leuk
Read more →NTLAIntellia Therapeutics Announces First Quarter 2020 Financial Results - On track to submit an IND or IND-equivalent for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020; plans to dose fir
Intellia Therapeutics Announces First Quarter 2020 Financial Results CAMBRIDGE, Mass., May 7, 2020 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo
Read more →NTLAIntellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer
CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) has named David Lebwohl, M.D., as its new executive vice president and chief medical officer. Dr. Lebwohl brings decades of biopharmaceutial leadership and drug development experience,
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates
CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its first quarter 2020 financial result
Read more →NTLAIntellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that five abstracts were accepted for the
Read more →NTLAIntellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results - On track to submit an IND application for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020 and to do
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 CAMBRIDGE, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo
Read more →NTLAIntellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results
On track to submit an IND application for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020 and to dose first patients in 2H 2020 Plans to submit an IND application for NTLA-5001, a WT1-directed TCR-T cell therapy, for the treatment of acute myeloid leukemia i
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2019 Earnings and Company Update
CAMBRIDGE, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present fourth quarter and full-year 2019 financ
Read more →NTLAIntellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference
Specific and potent tumor cell killing observed in WT1-positive acute myeloid leukemia blasts in vitro by TCR-based engineered T cells, supporting Intellia’s first engineered T cell therapy development candidate, NTLA-5001 Knockout of KLKB1 gene with CRISPR/Cas9 for hereditary a
Read more →NTLAIntellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones - On track to submit IND application for lead candidate, NTLA-2001 for transthyretin amyloidosis, in mid-2020 and dose first patients in 2H
Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones CAMBRIDGE, Mass. Jan. 9, 2020 - Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in
Read more →NTLAIntellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference
CAMBRIDGE, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the Evercore ISI 2nd Annual HealthCON
Read more →NTLAIntellia Therapeutics Announces Third Quarter 2019 Financial Results On track to submit in mid-2020 an investigational new drug application for NTLA-2001 for the treatment of transthyretin amyloidosis Expects to nominate
Intellia Therapeutics Announces Third Quarter 2019 Financial Results CAMBRIDGE, Mass., October 31, 2019 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA), reported operational highlights and financial results for the third quarter ended September 30, 2019. In 2019, we
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2019 Earnings and Company Update
CAMBRIDGE, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present third quarter 2019 results and operation
Read more →NTLAIntellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)
First reported consecutive in vivo gene knockout and insertion achieves therapeutically relevant results in an alpha-1 antitrypsin deficiency mouse model Inserted highly active WT1-TCR into the endogenous TCR locus for potential improved treatments for hematological and solid ma
Read more →NTLAIntellia Therapeutics Announces Presentations at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)
CAMBRIDGE, Mass., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced one oral presentation and four pos
Read more →NTLAIntellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update NTLA-2001: Intends to submit an investigational new drug application in mid-2020 for lead in vivo program for the treatment of tran
Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update CAMBRIDGE, Mass., Aug. 1, 2019 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA), reported operational highlights and financial results for the second quarter ended June 30, 2019.
Read more →NTLAIntellia Therapeutics to Present at August Healthcare Investor Conference
CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the following upcoming healthcare con
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company Update
CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present second quarter 2019 results and operatio
Read more →NTLAIntellia Therapeutics to Participate at June Healthcare Investor Conferences
CAMBRIDGE, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will participate in the following upcoming healthcare
Read more →NTLAIntellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer
CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc., (NASDAQ:NTLA) has named Laura Sepp-Lorenzino, Ph.D., as its new executive vice president and chief scientific officer. Dr. Sepp-Lorenzino brings decades of leadership and research and development exp
Read more →NTLAIntellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update Remains on track to submit investigational new drug application in 2020 for its first systemically delivered CRISPR/Ca
Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update CAMBRIDGE, Mass., May 2, 2019 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA), reported operational highlights and financial results for the first quarter ended March 31, 2019. A
Read more →NTLAIntellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update
Remains on track to submit investigational new drug application in 2020 for its first systemically delivered CRISPR/Cas9-based therapy, NTLA-2001, for treatment of transthyretin amyloidosis Expects to nominate first engineered cell therapy development candidate for treatment of
Read more →NTLAIntellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy
Intellia scientists advance CRISPR-mediated targeted gene insertion in non-human primates Achieved normal circulating human Factor IX protein levels in non-human primates using targeted gene insertion High rate and specificity of acute myeloid leukemia cell killing progressed
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company Update
CAMBRIDGE, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present first quarter 2019 results and operatio
Read more →NTLAIntellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy
CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced three oral presentations at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place April 29-May 2, 2019, in Washington, D.C. Intellia
Read more →NTLAIntellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results - Confirmed improved non-human primate liver editing and protein reduction of greater than 95 percent in transthyretin amyloidosis progr
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 techno
Read more →NTLAIntellia Therapeutics Names Fred Cohen, M.D., to Board of Directors
Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors CAMBRIDGE, Mass., January 24, 2019 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in v
Read more →NTLAIntellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia") within the meaning of the Private Securities Litigation Reform Act of 1995. Thes
Corporate Overview January 2019 Exhibit Intellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking
Read more →NTLAIntellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population Intellia's Right to Use Proprietary Lipid Nanoparticle Technology Extende
Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population CAMBRIDGE, Mass., Dec. 6, 2018 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focuse
Read more →NTLAIntellia Therapeutics to Present at November Healthcare Investor Conferences
CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will participate in the following upcoming healthcare
Read more →NTLAIntellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments
Enhanced in vivo CRISPR/Cas9 cargo components have led to substantially increased liver editing and protein reduction in non-human primates that could materially improve its transthyretin amyloidosis and other in vivo product profiles Integration of enhanced components into its
Read more →NTLAIntellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments Enhanced in vivo CRISPR/Cas9 cargo components have led to substantially increased liver editing and protein re
Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISP
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate Developments
CAMBRIDGE, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present third quarter 2018 results and corporate
Read more →NTLAIntellia Therapeutics Names Glenn Goddard as New Chief Financial Officer
CAMBRIDGE, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, has named Glenn Goddard its executive vice president
Read more →NTLAIntellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell Therapy
Intellia scientists present first robust demonstration of CRISPR-mediated insertion of transgenes in the liver Non-human primate data show high correlation achieved between liver edit and reduction of TTR protein High rate and specificity of acute myeloid leukemia cell killing
Read more →NTLAIntellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution
Robust, dose-responsive liver editing and reduction of TTR protein shown in humanized mouse model Therapeutically relevant reduction of serum TTR protein correlating with liver editing achieved in non-human primates after a single dose CAMBRIDGE, Mass., Aug. 23, 2018 (GLOBE N
Read more →NTLAIntellia Therapeutics to Host Educational Briefing Webinar on Interference Proceedings Relating to CRISPR/Cas9 Genome Editing Technology Patents
CAMBRIDGE, Mass., Aug. 23, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, will host an educational briefing session for investors addressing the interfe
Read more →NTLAIntellia Therapeutics Announces Second Quarter 2018 Financial Results Continued to progress lead in vivo program in transthyretin amyloidosis targeting submission of an Investigational New Drug application by the end of
Intellia Therapeutics Announces Second Quarter 2018 Financial Results CAMBRIDGE, Mass., Aug. 1, 2018 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, announced
Read more →NTLAIntellia Therapeutics Announces WT1 as Its First Cell Therapy Target, Following Presentation of Early Data at the American Society of Gene and Cell Therapy 21st Annual Meeting
CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, and its research collaborator, Ospedale San Raffaele (OSR), presented at the 21
Read more →NTLAIntellia Therapeutics Announces First Quarter 2018 Financial Results New CEO puts in vivo and ex vivo genome editing on parallel tracks towards the clinic Company anticipates submitting its in vivo Investigational New Dr
Intellia Therapeutics Announces First Quarter 2018 Financial Results CAMBRIDGE, Mass., May 1, 2018 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, an
Read more →NTLAIntellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results Initiated final testing of safety and efficacy in non-human primates (NHP) for our lead program intended to treat patients with transthy
Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR technolog
Read more →NTLAIntellia Therapeutics to Present at March Healthcare Investor Conferences
CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate at the following upcoming healthcare conferences in M
Read more →NTLAIntellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology
Intellia researchers achieved 97 percent reduction in serum transthyretin protein levels in mice through a single administration, with a durability of at least 12 months CRISPR/Cas9 administered via LNP was well-tolerated with no observed adverse events CRISPR/Cas9 components s
Read more →NTLAIntellia Therapeutics to Present at February Healthcare Investor Conferences
CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present or host one-on-one meetings at the following upcoming hea
Read more →NTLAIntellia Therapeutics Names John Leonard, M.D., President and Chief Executive Officer Dr. Leonard has successfully led the development and regulatory approval of breakthrough biopharmaceuticals Company s pipeline continu
Intellia Therapeutics Names John Leonard, M.D., President and Chief Executive Officer December 18, 2017 Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, has named John Leonard,
Read more →NTLAIntellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology Meeting
Data on ex vivo CRISPR/Cas9 genome-edited human hematopoietic stem cells shows increased production of fetal hemoglobin Approximately 80-95 percent editing was achieved in CD34+ cells Increased fetal hemoglobin levels were sustained for at least 16 weeks following transplant in
Read more →NTLAIntellia Therapeutics Announces Third Quarter 2017 Financial Results First company to demonstrate dose-dependent CRISPR/Cas9 liver editing in non-human primates, including editing of over 20 percent in certain animals, f
Intellia Therapeutics Announces Third Quarter 2017 Financial Results CAMBRIDGE, Mass., October 31, 2017 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR technology, announced
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2017 Earnings
CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present third quarter 2017 results to investors and analysts in a
Read more →NTLAIntellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal Study
First-in-class, one-year data demonstrate sustained TTR protein reduction of approximately 97 percent, corresponding to 70 percent liver editing, following a single in vivo systemic dose in mice Non-human primate studies ongoing and leading to development candidate designation i
Read more →NTLAIntellia Therapeutics to Present at Upcoming September Investor Healthcare Conferences
CAMBRIDGE, Mass., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at key September investor healthcare confere
Read more →NTLAIntellia Therapeutics Announces Second Quarter 2017 Financial Results In non-human primates, demonstrated robust green fluorescent protein expression throughout the liver 24 hours following a single, systemically deliver
Intellia Therapeutics Announces Second Quarter 2017 Financial Results CAMBRIDGE, Mass., August 1, 2017 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR tec
Read more →NTLAIntellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science and Technology Committee CAMBRIDGE, MASS.
Intellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science and Technology Committee CAMBRIDGE, MASS. July 24, 2017 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focu
Read more →NTLAIntellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China
CAMBRIDGE, Mass., June 19, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technology, today announced that China’s State Intellectual Property Office (“SIP
Read more →NTLAIntellia Therapeutics and San Raffaele University and Research Hospital to Combine CRISPR/Cas9 Genome Editing with Enhanced Cell Therapies to Fight Cancer
Research collaboration harnesses powerful CRISPR/Cas9 genome editing to engineer improved T-cell therapies targeting unmet needs in cancer Agreement builds on Intellia’s ex vivo approach through its division, eXtellia CAMBRIDGE, Mass., and MILAN, Italy, June 06, 2017 (GLOBE NEW
Read more →NTLAIntellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual Meeting
First-time data validates high levels of gene editing and reduction in serum transthyretin protein levels in rat models First to demonstrate single-dose, in vivo results using proprietary lipid nanoparticle delivery system in mice showing: approximately 97 percent reduction in s
Read more →NTLAIntellia Therapeutics Announces First Quarter 2017 Financial Results First to demonstrate single dose, in vivo results using a proprietary lipid nanoparticle delivery system showing: approximately 97 percent reduction in
Intellia Therapeutics Announces First Quarter 2017 Financial Results CAMBRIDGE, Mass., May 2, 2017 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technolo
Read more →NTLAIntellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes
CAMBRIDGE, Mass. and BASEL, Switzerland, April 26, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) and CRISPR Therapeutics AG (NASDAQ:CRSP), two leading genome editing companies focused on the development of potentially curative therapies, announced that the Un
Read more →NTLACRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision Appeal to the U.S. Court of Appeals for the Federal Circuit seeks review and reve
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision BASEL, Switzerland; CAMBRIDGE, Massachusetts; BERKELEY, California; DUBLIN, Ireland; April 13, 2017 (GLOBE NEWSWIRE) CRISPR Therapeutics (
Read more →NTLAIntellia Therapeutics Announces European Patent Office’s Decision to Grant CRISPR/Cas9 Genome Editing Technology Patent
Patent covers foundational CRISPR/Cas9 inventions that Intellia sublicensed for use in human therapeutics Patent covers compositions of CRISPR single guide RNA technology for use in non-cellular and cellular settings, including eukaryotic cells CAMBRIDGE, Mass., April 11, 2017
Read more →NTLAIntellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results First to demonstrate single dose, in vivo results, showing approximately 97 percent reduction in serum transthyretin prote
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results CAMBRIDGE, Mass., March 14, 2017 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics usi
Read more →NTLAIntellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results
First to demonstrate single dose, in vivo results, showing approximately 97 percent reduction in serum transthyretin protein levels Further established a comprehensive platform, including a proprietary lipid nanoparticle delivery system, to accelerate therapeutic development Ex
Read more →NTLAIntellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery Technology
First to demonstrate single dose, in vivo results, showing approximately a 97 percent reduction in serum transthyretin protein levels Durability data show stable liver editing for at least four months Increased liver editing efficiency reported to date at 70 percent, following
Read more →NTLAIntellia Therapeutics to Present at March Investor Healthcare Conferences
CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that company senior leaders will present at key
Read more →NTLAIntellia Therapeutics to Hold Conference Call to Address Patent Interference Proceedings
CAMBRIDGE, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA) will hold a conference call with investors on Thursday, February 16, 2017 at 8 a.m., EST. Investors are invited to dial into the conference call hosted by Nessan Bermingham, Ph.D., chief
Read more →NTLACRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K. - UC s patent applicatio
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K. BASEL, Switzerland, CAMBRIDGE, Mass., BERKELEY, California, DUBLIN, Ireland, Feb.
Read more →NTLAIntellia Therapeutics to Present at Leerink Partners 6th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Executive Officer and Founder Nessan
Read more →NTLAIntellia Therapeutics Joins Genomics England’s Industry Consortium
CAMBRIDGE, Mass. and LONDON, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics (NASDAQ:NTLA) has joined the Genomics England Genomics Expert Network for Enterprises (GENE) Consortium, as the first, dedicated genome editing company to participate in the 100,000 Genomes Proje
Read more →NTLAIntellia Therapeutics Names Graeme Bell Chief Financial Officer
CAMBRIDGE, Mass., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9 technology, has appointed Graeme Bell as its Chief Financial Officer. Mr. Bell
Read more →NTLAIntellia Therapeutics Opens New Headquarters as Company Continues to Advance CRISPR/Cas9 Platform and Pipeline
- Positions Intellia for R&D growth and progress toward clinical studies - - Accommodates hiring plans to support pipeline of CRISPR/Cas9 based therapeutics - CAMBRIDGE, Mass., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
Read more →NTLAIntellia Therapeutics Reports Financial Results for Third Quarter 2016 - First company to report high in vivo editing data using CRISPR/Cas9 in animal models - Further validation of lipid nanoparticle delivery platform -
Intellia Therapeutics Reports Financial Results for Third Quarter 2016 CAMBRIDGE, Mass., November 1, 2016 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/C
Read more →NTLAIntellia Therapeutics to Present at November Investor Healthcare Conferences
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that senior company leaders will present at key
Read more →NTLAIntellia Therapeutics to Present Data at the European Society of Gene & Cell Therapy Congress
CAMBRIDGE, Mass., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that members of its scientific team will present
Read more →NTLAIntellia Therapeutics to Present at Jefferies Gene Editing/Therapy Summit
CAMBRIDGE, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Medical Officer John Leonard, M.D., w
Read more →NTLAIntellia Therapeutics to Present at September Investor Healthcare Conferences
CAMBRIDGE, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that CEO and Founder Nessan Bermingham, Ph.D.,
Read more →NTLAIntellia Therapeutics’ Preclinical Data Show Continued Progress in In Vivo Gene Editing With Systemic Lipid Nanoparticle Delivery of CRISPR/Cas9 components
CAMBRIDGE, Mass., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, presented preclinical data demonstrating in vivo gene edit
Read more →NTLAIntellia Therapeutics to Present at 2016 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that CEO and Founder Nessan Bermingham, Ph.D., w
Read more →NTLAIntellia Therapeutics Reports Financial Results for Second Quarter 2016 Advancing proprietary and partnered pipeline candidates with Novartis and Regeneron Cash and cash equivalents of approximately $300.7 million to acc
Intellia Therapeutics Reports Financial Results for Second Quarter 2016 CAMBRIDGE, Mass., August 4, 2016 (GLOBE NEWSWIRE) Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Ca
Read more →NTLAIntellia Therapeutics to Present at the Jefferies 2016 Healthcare Conference and the International BIO Convention
CAMBRIDGE, Mass., June 03, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading gene editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at both the upcoming Jefferies 2016 Healthcare
Read more →NTLAIntellia Therapeutics Announces Closing of Initial Public Offering Underwriters Exercise Over-Allotment Option
Intellia Therapeutics Announces Closing of Initial Public Offering Underwriters Exercise Over-Allotment Option FOR IMMEDIATE RELEASE CAMBRIDGE, Mass., May 11, 2016 Intellia Therapeutics, Inc. (NASDAQ: NTLA) today announced the closing of its initial public offering of 6,900,0
Read more →NTLAIntellia Therapeutics, Inc. (Nasdaq: NTLA) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, May 11, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading gene-editing company, will visit the Nasdaq MarketSite in Times Square in celebration of its recent initial public offering (IPO) on May 6, 2016. In honor of the occasion, Nessan Ber
Read more →NTLAIntellia Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., May 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (”Intellia Therapeutics” or “Intellia”) a leading gene editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of its i
Read more →Competitive Position
How NTLA ranks across every disease it competes inCompetitive Position is a premium feature
See how NTLA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial